Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 5/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6708286 | 0.92 | KAT2B (0.40) | RPS6KB2KAT2BEGFRL3MBTL1MAPT | |
| SCHEMBL6708337 | 0.91 | KAT2B (0.41) | RPS6KB2KAT2BEGFRL3MBTL1MAPT | |
| SCHEMBL6706604 | 0.90 | KAT2B (0.42) | RPS6KB2KAT2BL3MBTL1MAPT | |
| SCHEMBL6708455 | 0.88 | RPS6KB2 (0.37) | RPS6KB2KAT2BEGFRKDM4EL3MBTL1 | |
| SCHEMBL6706646 | 0.86 | SELE (0.44) | RPS6KB2KDM4EL3MBTL1TDP1ALDH1A1 | |
| SCHEMBL6709557 | 0.81 | KAT2B (0.36) | RPS6KB2KAT2BKDM4EL3MBTL1MAPT | |
| SCHEMBL7096128 | 0.81 | PDE5A (0.43) | — | |
| SCHEMBL6708361 | 0.80 | HPGD (0.38) | RPS6KB2KAT2BKDM4EL3MBTL1MAPT | |
| SCHEMBL6708375 | 0.79 | HPGD (0.40) | KAT2BKDM4EL3MBTL1MAPTALDH1A1 | |
| SCHEMBL6706662 | 0.79 | SELE (0.42) | KAT2BKDM4EMAPTTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077664-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates | MERCK PATENT GMBH (DE) | 2004-04-22 | — | — | US | disclosed |
| US-20040072846-A1 | Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives | MERCK PATENT GMBH (DE) | 2004-04-15 | — | — | US | disclosed |
| US-20040063731-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | MERCK PATENT GMBH (DE) | 2004-04-01 | — | — | US | disclosed |
| US-20040034040-A1 | Use of thienopyrimidines | MERCK PATENT GMBH (DE) | 2004-02-19 | — | — | US | disclosed |
| EP-1357915-A2 | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK PATENT GmbH (DE) | 2003-11-05 | — | — | EP | disclosed |
| US-6495554-B2 | PHOSPHODIESTERASE V INHIBITORS, TREATING CARDIOVASCULAR DISORDERS, AND THERAPY OF ERECTILE DYSFUNCTION. | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2002-12-17 | — | — | US | disclosed |
| US-20020132818-A1 | Thienopyrimidines | MERCK PATENT GMBH (DE) | 2002-09-19 | — | — | US | disclosed |
| WO-2002062343-A2 | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2002-08-15 | — | — | WO | disclosed |
| US-6420368-B1 | DISEASES OF THE CARDIOVASCULAR SYSTEM AND FOR TREATMENT AND/OR THERAPY OF ERECTILE DYSFUNCTION. | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2002-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077664-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates | PTGIS, DPYD, PTGIR | RPS6KB2 3097/4885KAT2B 4660/4885EGFR 3826/4885 |
| US-20040063731-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | EDNRA, EDNRB, PTGIR | RPS6KB2 3401/4885KAT2B 4824/4885EGFR 912/4885 |
| US-20040034040-A1 | Use of thienopyrimidines | DPYD, TBXAS1, TYMS | RPS6KB2 1799/4885KAT2B 4709/4885EGFR 3741/4885 |
| US-20020132818-A1 | Thienopyrimidines | PDE5A, PDE3B, PDE3A | RPS6KB2 4126/4885KAT2B 3999/4885EGFR 4875/4885 |
| US-20040072846-A1 | Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives | PTGER1, TBXA2R, PTGIS | RPS6KB2 2013/4885KAT2B 4003/4885EGFR 3314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.